The December 1 issue of The ASCO Post contains two articles that will be of interest to many patients with progressive disease and their family members. The first article, by Matthew Stenger, is a summary of the recently released ASCO/CCO guideline on the systemic treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) with drugs […]![]()
